[ad_1]
Image source,fake images
The latest data published by Brazil shows that the global effective rate of the Coxing vaccine is 50.4%.
The latest data published by Brazil shows that the overall effective rate of the new coronavirus vaccine developed by Sinovac Biotech is 50.4%. This figure barely reaches the threshold required by world regulators, but is well below the 78% announced by Brazil last week.
The data was presented by the Butantan Institute in Sao Paulo to the Brazilian health regulator on Tuesday (January 12). The Butantan Institute is a partner of Kexing Biotech and is currently conducting the final phase of clinical trials of this vaccine in Brazil.
Researchers from the Institute explained that the decrease in the effective rate was due to the inclusion of patients who were infected with the new coronavirus but who only showed “very mild” symptoms.
“Very mild” symptoms
Last week, Brazilian researchers announced that the Coxing vaccine trial had an effective rate of 78%, which they later called the “clinical effective rate.”
The researchers explained in a press conference on Tuesday (January 12) that they classified these cases as asymptomatic, very mild, mild, moderate and severe.
Image source,EPA
Despite the severity of the epidemic, the streets of São Paulo are still overcrowded.
According to the Institute report, 78% of the previous “clinical effective rate” considered mild, moderate and severe cases, but if patients with “very mild” symptoms are included among the volunteers, the new “general effective rate” The figure is 50.4%. These people do not need medical assistance.
The researchers emphasized that this vaccine is still 78% effective in preventing mild cases that require treatment and 100% effective in moderate to severe cases.
Currently, the World Health Organization and national regulatory agencies generally set the effective rate of 50% as the threshold for qualification of the vaccine.
“This vaccine reduces the intensity of the disease,” said Ricardo Palacios, medical director of the Butantan Institute. He argued that the trial was conducted with medical personnel highly exposed to the virus and that the interval between the two doses was very short and that if it was extended to a wider community, the effect could be better.
Image source,EPA / WU HONG
The Butantan Institute also stated that the biggest side effects of the Koxing vaccine are local pain, headache and fatigue, but there is no record of serious side effects.
Brazil is one of the countries most affected by the new corona epidemic in the world. More than 8 million people have been infected with the new corona virus and the number of deaths ranks second in the world. The federal government is ready to start vaccinating people with two vaccines, this is one of them, which has caused many people to pay close attention to the test results.
Microbiologist Natalia Pasternak told reporters that the test results mean the vaccine is not a panacea.
“This is not the best vaccine in the world,” he said, but said it was a “totally acceptable vaccine.”
Different results
This vaccine called “CoronaVac” (CoronaVac) developed by China Kexing Biotechnology is an inactivated vaccine made from killed pathogens, which mainly induces the production of cellular immunity through the antigens it contains. It will not cause serious reactions to diseases.
According to the New York Times, Kexing has sold more than 300 million vaccines, mainly to low- and middle-income countries, representing about half of the total production capacity of vaccine manufacturers launched by China in 2020.
Many countries, including Indonesia, Turkey, and Singapore, have called for this vaccine, but it has different results in clinical trials in different countries.
Image source,fake images
Turkey has also purchased Coxing vaccines.
Last month, Turkish researchers claimed that the effective rate of this vaccine was 91.25%, while Indonesia, which gave Koxing the green light on Monday, announced that its effective rate was 65.3%. Both are interim results of phase III clinical trials.
In contrast, the United States Pfizer / BioNTech and Modena (Moderna) reported 95% and 94.1% respectively, and the Oxford / AstraZeneca vaccine has an effective rate of 70.4%.
However, the two vaccines from Coxing and Oxford / AstraZeneca have the same advantages: there is no need for ultra-low temperature storage, just a refrigerator refrigeration environment. But the Modena vaccine should be stored at minus 20 degrees Celsius, while the Pfizer / BioNTech vaccine should be stored at minus 70 degrees Celsius.
This means that the first two can be used more effectively in developing countries, because those places may not have enough cryogenic storage facilities for the storage of vaccines.
On Wednesday (January 13), Indonesian President Joko Widodo publicly vaccinated Kexing’s vaccine on live television.
The Kexing vaccine has not yet announced the results of phase III clinical trials in China nor has it been approved for marketing. The China National Medical Products Administration approved a vaccine under the company’s national competitor Sinopharm Group on December 31 last year.
Hundreds of citizens in Yiwu, China line up to “snatch” the new crown vaccine “I feel like the new crown is far from me.”
However, China soon granted the emergency use permit for the Kexing vaccine. In November last year, many cities in Zhejiang provided the Kexing vaccine to people in need.
Brazil’s dilemma
Despite being the most affected country in Latin America, Brazil’s vaccination work has not progressed smoothly.
BBC World Station Americas editor Candace Piette (Candace Piette) reported that Brazil has not announced a clear schedule for national vaccination. This delay is due in large part to government disorder and fragmentation of vaccines.
Image source,Reuters
President Jair Bolsonaro has long rejected vaccines and, without providing proof, said that most Brazilians are reluctant to get vaccinated.
He criticized the Coxing vaccine more harshly and banned the federal government from purchasing, but later withdrew the decision. Political analysts believe this is mainly due to his political opponent, Sao Paulo Governor João Doria, who is a strong supporter of the vaccine.
Brazil’s national immunization program is currently based on the Coxinghe and Oxford / AstraZeneca vaccines, but both are awaiting approval from Brazilian health regulators.
